Skip to main content
Premium Trial:

Request an Annual Quote

Isis Licenses Antisense Tools to Merck

NEW YORK, Feb. 21 - Isis Pharmaceuticals has struck a deal with Merck to provide the pharmaceutical giant with antisense tools for drug-target validation, the company said on Thursday.

 

Under the agreement, Merck will use Isis antisense techniques to probe the biological function of genes of interest, and ascertain their utility as potential drug targets.

 

The two companies have other collaborations: Isis licensed a type 2 diabetes drug candidate to Merck in 2001, and the two firms are partnering in a hepatitis C drug discovery program.

The Scan

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.